

THE GASTROENTEROLOGY GROUP, P.A.

DIPLOMATES OF THE AMERICAN BOARD OF
INTERNAL MEDICINE AND GASTROENTEROLOGY

JOHN J. KRAVITZ, M.D., F.A.C.G.
JOHN A. VOLPE, D.O.
DAVID R. SALOWE, M.D.
CRAIG R. BARASH, M.D.

November 13, 2000


Docket Management Branch
Food and Drug Administration
Department of Health Services
Room 1-23
12420 Parklawn Drive
Rockville, MD 20857

RE: DOCKET #00P-1499/CPI

Dear Sir:

I wish to voice my support for the continued use of Lotronex, a drug that has been produced by Glaxo Wellcome Company for better control of diarrheal component, as well as abdominal pain and bloating of irritable bowel syndrome. I found this drug, when used in the correct fashion, as indicated by the insert with the drug, is quite effective in controlling rather severe symptoms for patients of mine who have literally become reclusive because of attacks of loose stool. As you may be aware, there are no drugs on the market which control the symptoms in as effective a way without causing significant side effects. I believe continued judicious use of this drug would be advantageous to the public. As mentioned before, when used properly, there should be little or no side effects.

Sincerely yours,


John J. Kravitz, M.D.

JJK/cjb


cc: Lauren Dowd-Ivancienko
Glaxo Wellcome, Inc.
3102 Dixon Avenue
Bristol, PA 19007

00P-1499

033

GASTROENTEROLOGY GROUP, PA.

d Crossing
xford Valley Road, Suite 402
s Hills, PA 19030



Docket Management Branch
Food and Drug Administration
Department of Health Services
Room 1-23
12420 Parklawn Drive
Rockville, MD 20857

